Shilpa Medicare informs about company updates

Shilpa Medicare has informed that the Company has received an approval from the United States Food & Drug Administration (USPDA) for Azacitidine - Injection Anda of SEZ Formulations Facility situated at Jadcherla, near Hyderabad.

The above information is a part of company’s filings submitted to BSE.